Compare SPCB & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPCB | INTS |
|---|---|---|
| Founded | 1988 | 2012 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.8M | 12.4M |
| IPO Year | 2004 | 2021 |
| Metric | SPCB | INTS |
|---|---|---|
| Price | $11.61 | $4.47 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $38.00 |
| AVG Volume (30 Days) | ★ 86.1K | 22.8K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $27.13 | N/A |
| P/E Ratio | $10.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.07 | $0.19 |
| 52 Week High | $13.57 | $8.06 |
| Indicator | SPCB | INTS |
|---|---|---|
| Relative Strength Index (RSI) | 67.30 | 28.33 |
| Support Level | $7.72 | $0.31 |
| Resistance Level | $12.18 | $8.06 |
| Average True Range (ATR) | 0.67 | 0.21 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 84.78 | 5.86 |
SuperCom Ltd is an Israel-based provider of traditional and digital identity solutions, providing safety, identification, tracking, and security products to governments and organizations. The company comprises three main Strategic Business Units: e-Gov; IoT, which is the key revenue driver; and Cyber Security. The Company's IoT products and solutions reliably identify, track and monitor people or objects in real time, enabling the customers to detect unauthorized movement of people, vehicles and other monitored objects. The geographical segments of the company include Africa, European countries, South America, the United States, Israel, and APAC.
Intensity Therapeutics Inc . is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.